Compare VIR & GIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | GIII |
|---|---|---|
| Founded | 2016 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2019 | 2006 |
| Metric | VIR | GIII |
|---|---|---|
| Price | $9.36 | $31.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 5 |
| Target Price | $19.43 | ★ $29.00 |
| AVG Volume (30 Days) | ★ 1.6M | 324.9K |
| Earning Date | 05-06-2026 | 06-05-2026 |
| Dividend Yield | N/A | ★ 1.29% |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ 1.51 |
| Revenue | $68,556,000.00 | ★ $2,957,012,000.00 |
| Revenue This Year | $270.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.80 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $20.33 |
| 52 Week High | $11.66 | $34.83 |
| Indicator | VIR | GIII |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | 58.78 |
| Support Level | $8.47 | $28.28 |
| Resistance Level | $10.29 | $32.61 |
| Average True Range (ATR) | 0.47 | 0.81 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 8.48 | 56.53 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
G-III Apparel Group Ltd is an apparel manufacturing company. The company makes a wide range of apparel, footwear, and accessories that sells under its own brands, licensed brands, and private-label brands. It has a substantial portfolio for licensed and proprietary brands, anchored by brands: DKNY, Donna Karan, Karl Lagerfeld, Karl Lagerfeld Paris, Vilebrequin, and others. The reportable segments of the company are Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, and sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenue from Wholesale operations.